P

Pfizer

Makes cancer drugs, vaccines and other medicines

TUKYSA Marketing Team Lead

Full-TimeUpdated on 10/23/2026
No salary listed
Senior
Bachelor's
Tokyo, Japan
In Person
Growth & MarketingBrand & Creative Marketing

About the job

Requirements
  • A bachelor's degree or equivalent is required.
  • A minimum of five years of pharmaceutical marketing experience is required.
  • Demonstrated experience in brand strategy, Brand Planning, financial forecasting, performance management, and promotional-budget management is required.
  • Experience leading complex cross-functional projects or initiatives in a matrix organization is required.
  • Strong strategic thinking, financial acumen, analytical capability, and problem-solving skills are required.
  • Demonstrated ability to influence senior stakeholders and align multiple functions without formal authority is required.
  • Strong written and verbal communication and presentation skills in both Japanese and English are required.
  • High standards of integrity, compliance, collaboration, and patient focus are required.
Responsibilities
  • Deliver agreed revenue, profitability, and business performance objectives for TUKYSA.
  • Lead financial planning and forecasting, including the Operating Plan, long-range forecasts, latest estimates, and business scenarios.
  • Monitor financial and non-financial KPIs, address performance gaps, and lead timely corrective actions.
  • Manage the promotional budget and recommend effective allocation of financial and other resources.
  • Partner with Finance, Analytics, Supply, and other functions to manage business risks and opportunities.
  • Develop and execute the long-term TUKYSA franchise strategy, annual Brand Plan, and Plan of Action for Japan.
  • Define strategic priorities, growth opportunities, sources of business, and investment choices across indications.
  • Translate scientific evidence, market dynamics, and customer and patient insights into a differentiated value proposition and actionable commercial strategy.
  • Optimize positioning, segmentation, targeting, customer engagement, promotional strategy, and channel mix.
  • Adapt Global and International strategies to the Japanese market and ensure that Japan perspectives are appropriately represented.
  • Lead the sustainable growth and ongoing performance of the existing TUKYSA business.
  • Lead commercial strategy, readiness, and execution for planned indication expansions, including market shaping, positioning, targeting, customer journeys, key messages, field readiness, and post-launch optimization.
  • Lead commercial input into opportunity assessments, forecasts, investment decisions, and scenario planning.
  • Establish clear milestones, governance, KPIs, risk assessments, and mitigation plans.
  • Monitor market dynamics, competitive developments, treatment patterns, customer insights, field feedback, and launch performance, and adjust plans as needed.
  • Lead the TUKYSA cross-functional team and align stakeholders around a common strategy, priorities, milestones, and measures of success.
  • Partner closely with Medical Affairs, Market Access, Regulatory Affairs, Analytics, Finance, Supply, Legal, Compliance, Sales teams, and other relevant functions.
  • Clarify roles, responsibilities, decision rights, and escalation pathways, and proactively resolve issues.
  • Provide strategic direction, coaching, and development support to TUKYSA Marketing colleagues and project members without direct people-management responsibility.
  • Represent the TUKYSA business in relevant Japan, International Commercial, and Global forums.
  • Ensure high-quality and timely execution of Brand Plans, launch plans, promotional materials, training programs, congress activities, and customer-facing initiatives.
  • Establish effective governance and performance-review processes for the TUKYSA business.
  • Partner with Supply and relevant functions to anticipate demand and address potential supply or business-continuity risks.
  • Ensure compliance with applicable laws, regulations, industry codes, Pfizer policies, and internal review and approval processes.
  • Demonstrate high standards of integrity, sound judgment, and patient focus in all business decisions.
Desired Qualifications
  • Experience in oncology, breast cancer, specialty care, or another complex therapeutic area.
  • Experience leading a new product launch or indication expansion.
  • Experience managing an established business while preparing for a future launch.
  • Experience working with International Commercial, regional, or Global teams.
  • Experience providing functional leadership, coaching, or development support to colleagues.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.